From the Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences (R.L.J., A.V.V., O.H.L.-V., L.E., L.I., D.N.S.-M., T.M., Z.A.M., D.C.P., J.P., A.S., M.L.G.-T., H.J.R., B.L.M., G.D.R.), and Department of Radiology and Biomedical Imaging (G.D.R.), University of California, San Francisco; Department of Diagnostic Imaging (O.H.L.-V.), Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Molecular Biophysics and Integrated Bioimaging Division (S.L.B., M.J., W.J.J., G.D.R.), Lawrence Berkeley National Laboratory; and Helen Wills Neuroscience Institute (W.J.J., G.D.R.), University of California Berkeley.
Neurology. 2021 Feb 2;96(5):e650-e661. doi: 10.1212/WNL.0000000000011270. Epub 2020 Dec 1.
To assess whether Alzheimer disease (AD) clinical presentation and relate to the burden and topography of β-amyloid (Aβ) and tau pathologies using in vivo PET imaging.
We studied 119 Aβ-positive symptomatic patients aged 48-95 years, including 29 patients with logopenic variant primary progressive aphasia (lvPPA) and 21 with posterior cortical atrophy (PCA). Pittsburgh compound B (PiB)-Aβ and flortaucipir (tau)-PET standardized uptake value ratio (SUVR) images were created. General linear models assessed relationships between demographic/clinical variables (phenotype, age), , and PET (including global cortical and voxelwise SUVR values) while controlling for disease severity using the Clinical Dementia Rating Sum of Boxes.
PiB-PET binding showed a widespread cortical distribution with subtle differences across phenotypes and was unrelated to demographic/clinical variables or . Flortaucipir-PET was commonly elevated in temporoparietal regions, but showed marked phenotype-associated differences, with higher binding observed in occipito-parietal areas for PCA, in left temporal and inferior frontal for lvPPA, and in medial temporal areas for other AD. Cortical flortaucipir-PET binding was higher in younger patients across phenotypes ( = -0.63, 95% confidence interval [CI] -0.72, -0.50), especially in parietal and dorsal prefrontal cortices. The presence of was associated with a focal medial temporal flortaucipir-SUVR increase, controlling for all other variables (entorhinal: + 0.310 SUVR, 95% CI 0.091, 0.530).
Clinical phenotypes are associated with differential patterns of tau but not amyloid pathology. Older age and are not only risk factors for AD but also seem to affect disease expression by promoting a more medial temporal lobe-predominant pattern of tau pathology.
使用体内正电子发射断层扫描(PET)成像评估阿尔茨海默病(AD)的临床表现与β-淀粉样蛋白(Aβ)和tau 病理学负担和分布的关系。
我们研究了 119 名 Aβ 阳性症状患者,年龄 48-95 岁,包括 29 名语言流畅性变异原发性进行性失语症(lvPPA)患者和 21 名后部皮质萎缩(PCA)患者。制作匹兹堡化合物 B(PiB)-Aβ 和氟脱氧酪氨酸(tau)-PET 标准化摄取值比值(SUVR)图像。一般线性模型评估了人口统计学/临床变量(表型、年龄)、和 PET(包括皮质全局和体素 SUVR 值)之间的关系,同时使用临床痴呆评定量表总分为 Boxes 评估疾病严重程度进行控制。
PiB-PET 结合显示出广泛的皮质分布,表型之间存在细微差异,与人口统计学/临床变量或无关。氟脱氧酪氨酸-PET 在颞顶叶区域通常升高,但表现出明显的表型相关差异,PCA 患者顶枕区域结合更高,lvPPA 患者左颞叶和下额叶结合更高,其他 AD 患者内侧颞叶区域结合更高。皮质氟脱氧酪氨酸-PET 结合在所有表型的年轻患者中均较高(= -0.63,95%置信区间[CI] -0.72,-0.50),尤其是顶叶和背侧前额叶皮质。存在淀粉样蛋白沉积与内侧颞叶氟脱氧酪氨酸 SUVR 增加有关,在控制所有其他变量后(内嗅皮质:+0.310 SUVR,95%CI 0.091,0.530)。
临床表型与 tau 病理学的不同模式有关,而与淀粉样蛋白病理学无关。年龄较大和淀粉样蛋白沉积不仅是 AD 的危险因素,而且似乎还通过促进更内侧颞叶为主的 tau 病理学模式来影响疾病的表达。